Groundbreaking Study Shows GLP-1RAs Significantly Reduce Death Rate in Psoriasis Patients

Reduction of Risks in Psoriasis Patients Using GLP-1RA

Psoriasis, a chronic skin condition affecting 2-3% of the global population, has long been linked to not only visible symptoms but also an increased risk of severe health issues such as heart attacks, strokes, and mental health disorders, including depression and anxiety. Recent groundbreaking research presented at the EADV Congress 2025 has shed light on the potent benefits of Glucagon-like Peptide-1 receptor agonists (GLP-1RAs) for patients suffering from psoriasis.

The study, the largest of its kind, has shown that psoriasis patients treated with GLP-1RAs have a staggering 78% lower mortality risk and a 44% reduction in the likelihood of experiencing major cardiovascular events when compared to those on alternative diabetes and weight-loss medications. This noteworthy finding positions GLP-1RAs not only as a treatment for Type 2 diabetes and obesity but also as a potential game-changer for psoriasis management.

Study Details

Researchers analyzed data from an extensive database encompassing over 110 million patients in the United States. The analysis focused on more than 6,000 psoriasis patients, specifically comparing two groups: one that received GLP-1RAs, including Semaglutide and Liraglutide, and another that was treated with other diabetes and obesity medications. The outcomes were measured over a period of two years, with results adjusted for age, gender, and existing health conditions.

The evidence indicated consistent benefits from GLP-1RAs across various sensitivity analyses, which utilized propensity score matching to mitigate the impact of potential confounding variables. A lead author of the study, Professor Ralf Ludwig, commented on the findings, emphasizing that GLP-1RAs might help reduce cardiovascular and psychiatric risks in psoriasis patients beyond their weight and blood sugar control capabilities.

Psychological and Behavioral Benefits

Interestingly, the study also revealed a significant decrease in substance abuse issues among psoriasis patients undergoing GLP-1RA therapy, showing a 65% reduction in alcohol misuse and nearly 50% for drug abuse. The mechanisms at play may include the ability of GLP-1RAs to inhibit pro-inflammatory mediators typically elevated in psoriasis, alongside their expression in brain regions associated with mood and reward systems—potentially explaining the observed decreases in alcohol and drug dependency.

Implications of the Findings

The advantages highlighted in the research indicate that GLP-1RAs could significantly transform treatment protocols for psoriasis patients, especially those concurrently managing diabetes or weight concerns. The safety profile of GLP-1RAs aligned closely with that of the general population, with no substantial increase in adverse events like hypoglycemia, nausea, or constipation.

Professor Ludwig concluded the study by suggesting that given their safety and diverse benefits, GLP-1 receptor agonists could soon be favored as a treatment choice for psoriasis patients requiring assistance with diabetes or weight management. As the medical community continues to explore the expansive horizon of psoriasis treatment, the findings from the EADV Congress 2025 undoubtedly pave the way for improved health outcomes for millions worldwide.